by Rod Raynovich | Jun 7, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Biopharmaceutical stocks got a boost today from a rally in NASDAQ stocks and some positive news on cancer drugs from ASCO. The IBB ($106.36) was up 1.6% off its YTD and all time high of $110 and a nice rally after five days of weakness.The XBI was also up 1.97%. Many...
by Rod Raynovich | Jun 6, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Speculation in small cap biopharmaceutical stocks has peaked and we urged weeks ago to raise cash positions to 10-15%. The ASCO “sell on the news effect” has continued today with some high fliers off significantly: Exelixis (EXEL $8.95) is off 18% after...
by Rod Raynovich | May 31, 2011 | 2024-25 Life Science Portfolios, BIOgraph
The life science market continued to show resilience today with a few big movers and a bidding up of large cap drugs such as Johnson and Johnson (JNJ $67.15), Novartis (NVS $64.24), Pfizer(PFE $21.21) and Sanofi-Aventis (SNY $39.42). Foreign drug companies fared...
by Rod Raynovich | May 27, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Our recent article on biotech investing and ETF’s in general are posted on Investor Uprising. Note to get the article on the right side of the page you need to register at no charge for Investor Uprising. Investor Uprising – IU Education – Guide to...
by Rod Raynovich | May 25, 2011 | 2024-25 Life Science Portfolios, BIOgraph
A bull market in life science stocks has revved up news for the upcoming ASCO Meeting on June 3 in Chicago. We will provide limited coverage of stocks to watch and scientific articles of interest. However it is clear that many PR shops and newsletters are busy...
by Rod Raynovich | May 23, 2011 | 2024-25 Life Science Portfolios, BIOgraph
It was a nasty day from the beginning but losses abated as the day wore on. The NASDAQ was off 1.68%, the Dow down 1.05% and the S&P down 1.15% to 1317. The S&P held trend lines in the 1312-1315 range. Biotech ETF’s were also losers IBB off 1.5%, FBT off...
by Rod Raynovich | May 20, 2011 | 2024-25 Life Science Portfolios, BIOgraph
The pre-ASCO hype has already begun but many biopharma stocks have already run up 15%+ YTD. So it is time to be cautious as there may be an “ASCO Effect”- a sell on the news effect. Despite a weak tape in the major indices the life science sector has a lot...
by Rod Raynovich | May 19, 2011 | 2024-25 Life Science Portfolios, BIOgraph
M&A Premium Rocks On In a flat life science market eclipsed by the LinkedIn (LNKD) IPO and its day trading frenzy, many life science stocks in the Rayno Life Science Portfolio logged decent gains. As reported earlier today GenProbe(GPRO) sold off down 4.37% but it...
by Rod Raynovich | May 19, 2011 | 2024-25 Life Science Portfolios, BIOgraph
But ThermoFisher (TMO $65.12) is Up 3.78% on Volume of 3.2M Shares GenProbe (GPRO $84.10) down 2.9% sold off some of of the speculative gains from yesterday after ThermoFisherScientific (TMO) announced it was buying Phadia, a privately held Swedish diagnostic Company...
by Rod Raynovich | May 18, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Speculation chat is driving up shares of GenProbe (GPRO) on heavier volume of 2.5M shares. Two stories are notable one from the Wall Street Journal on ThermoFisher (TMO) a potential bidder, but also interested in Phadia AB an allergy testing Co., and the other on a...
